31 C
Vientiane
Tuesday, June 3, 2025
spot_img
Home Blog Page 93

Antengene to Present Latest Clinical Results from Two Studies in CPI-resistant Solid Tumors at ASCO 2025

  • ATG-037, an oral small molecule CD73 inhibitor, in combination with MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), achieved an overall response rate (ORR) of 36.4% and disease control rate (DCR) of 100% in checkpoint inhibitor (CPI)-resistant melanoma patients in the ongoing STAMINA-01 trial, with one patient maintaining a partial response (PR) and remained on treatment for over 2 years without any safety concerns.
  • In CPI-resistant non-small cell lung cancer (NSCLC), the combination of ATG-037 and pembrolizumab achieved an ORR of 22% and DCR of 67% in the same study.
  • ATG-008, an oral dual mTORC1/2 inhibitor, in combination with toripalimab, achieved an ORR of 22.2% and DCR of 85.2% in CPI-resistant cervical cancer patients in the ongoing TORCH-2 trial.

SHANGHAI and HONG KONG, May 23, 2025 /PRNewswire/ — Antengene Corporation Limited (“Antengene“, SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematologic malignancies and solid tumors, today announced that it will present the latest clinical data of its CD73 oral small molecule inhibitor ATG-037 and oral dual mTORC1/2 inhibitor ATG-008 in Poster Presentations at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 30th to June 3rd in Chicago, IL, the United States.

Details of the Poster Presentations:
ATG-037 (CD73 Small Molecule Inhibitor)
Title: A First-In-Human Phase I/Ib study of ATG-037 Monotherapy and Combination Therapy with Pembrolizumab in Patients with Advanced Solid Tumors – STAMINA-01
Abstract: 3123
Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Date: June 2, 2025
Time: 1:30 PM – 4:30 PM (Central Time)
          2:30 AM – 5:30 AM, June 3, 2025 (Beijing Time)

  • Robust clinical benefit observed in CPI-resistant patients: As of April 27, 2025, the study has already completed the dose escalation part in which 43 patients were enrolled and received monotherapy. Among them, 28 CPI-resistant patients also received the combination therapy. Among patients treated with the combination therapy, 6 patients (4 melanoma and 2 NSCLC patients) achieved a confirmed PR with an ORR of 21.4%, and 16 patients achieved stable disease (SD) with a DCR of 78.6%. The combination regimen delivered particularly encouraging efficacy in melanoma, with all 11 CPI-resistant patients achieving disease control (DCR 100%) and an ORR of 36.4% (4 PRs), including 1 patient having maintained PR and remained in the study for over 2 years without any safety concerns. In CPI-resistant NSCLC, the combination regimen achieved an ORR of 22% (PRs) and a DCR of 67%. These results highlight the potential of ATG-037 to deliver meaningful clinical benefit across multiple tumor types, reinforcing its promise as a novel treatment option in CPI-resistant cancers.
  • Manageable safety profile: Treatment-related adverse events were reported in 56% (24/43) of patients receiving monotherapy and 61% (17/28) of patients receiving the combination therapy. The majority of these TRAEs were grade 1-2. Only one serious TRAE (grade 3 immune mediated hepatitis) was observed in the study.
  • Two key differentiators: ATG-037 is an oral small molecule CD73 inhibitor offering greater convenience over intravenous (IV) injectable agents and is uniquely designed to overcome the ‘hook effect’ commonly seen in anti-CD73 antibodies, enabling complete and more effective CD73 inhibition.
  • The STAMINA-01 trial: STAMINA-01 is a Phase I/Ib study jointly conducted by Antengene and MSD (Merck & Co., Inc., Rahway, NJ, USA). The study was designed to evaluate the safety, pharmacokinetics, and optimal dosing of ATG-037 as a monotherapy and in combination with MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with refractory/relapsed solid tumors. At present, dose optimization and dose expansion parts of the study are being carried out as planned in China and Australia.

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

ATG-008 (mTORC1/2 Small Molecule Inhibitor)
Title: A TORC1/2 inhibitor onatasertib combined with toripalimab in patients with advanced cervical cancers with prior anti-PD-(L)1 therapy
Abstract: 5540
Session: Gynecologic Cancer
Date: June 1, 2025
Time: 9:00 AM – 12:00 PM (Central Time)
          10:00 PM, June 1, 2025 – 1:00 AM, June 2, 2025 (Beijing Time)

  • The TORCH-2 trial: ATG-008 is an oral dual mTOR1/2 inhibitor. The TORCH-2 trial is a Phase I/II dose escalation and dose expansion study of ATG-008 in combination with the anti-PD-1 monoclonal antibody toripalimab in patients with advanced solid tumors. This abstract reports data from patients with advanced cervical cancer who had previously received at least prior 1 line of anti-PD-(L)1 therapy and 1 line of platinum chemotherapy, regardless of the PD-L1 expression. As of November 25, 2024, 30 qualified patients were enrolled and received ATG-008 15 mg orally once a day (QD) in combination with toripalimab 240 mg, once every 21 days (Q3W). Among them, 14 and 16 patients had received 1 and at least 2 prior lines of systemic therapy, respectively. The median time since initial diagnosis was 37 months.
  • Encouraging efficacy in patients with CPI-resistant cervical cancer: Among 27 efficacy-evaluable patients, the combination regimen achieved an ORR of 22.2% and a DCR of 85.2%. The ORRs of PD-L1 positive and PD-L1 negative populations were 30% (3/10) and 33.3% (2/6), respectively. The median time to response was 1.7 months (1.4, 4.2) and the median duration of response (DOR) was 5.7 months (95% CI: 2.7, NE). The median progression-free survival (PFS) was 4.2 months (95% CI: 3.3, 5.8) and the median overall survival (OS) was 21.4 months (95% CI: 15.5, NE). These results underscore the potential of ATG-008 in combination with toripalimab in providing meaningful clinical benefit for CPI-resistant cervical cancer patients, reinforcing its promise as a novel treatment option for this difficult-to-treat patient population.
  • Manageable safety profile: All 30 patients experienced at least one TEAE, and 22 patients (73.3%) reported grade ≥3 TRAEs. The most common all-grade TRAEs were hyperglycaemia (56.7%), rash (43.3%) and white blood cell decreased (43.3%). Most TRAEs were grade 1-2, and no TEAE led to death.

About Antengene

Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of “Treating Patients Beyond Borders”.

Antengene has built a pipeline of 9 oncology assets at various stages going from clinical to commercial, including 6 with global rights, and 3 with rights for the APAC region. To date, Antengene has obtained 31 investigational new drug (IND) approvals in the U.S. and Asia, and submitted new drug applications (NDAs) in 11 Asia Pacific markets, with the NDA for XPOVIO® (selinexor) already approved in Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia.

Forward-looking statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company’s Annual Report for the year ended December 31, 2024, and the documents subsequently submitted to the Hong Kong Stock Exchange.

For more information, please contact:

Investor Contacts: 
Donald Lung
E-mail: Donald.Lung@antengene.com  
Mobile: +86 18420672158

PR Contacts:
Peter Qian
E-mail: Peter.Qian@antengene.com 
Mobile: +86 13062747000

US Govt Revokes Harvard’s Right to Enroll Foreign Students

(FILES) Harvard sweatshirts are displayed for sale in a school store window on the Harvard University campus in Cambridge, Massachusetts, on April 15, 2025. US President Donald Trump's administration on Thursday revoked Harvard's right to enroll foreign students -- more than a quarter of its annual enrollment -- in a major escalation of the president's fight with one of the world's most storied universities. Trump is furious at Harvard -- which has produced 162 Nobel prize winners -- for rejecting his demand that it submit to oversight on admissions and hiring over his claims that it is a hotbed of anti-Semitism and "woke" liberal ideology. (Photo by Joseph Prezioso/AFP)

By Gregory WALTON/AFP – Donald Trump’s administration on 22 May revoked Harvard’s ability to enroll foreign nationals, more than a quarter of the student body, in a quick escalation of the US president’s fight against the prestigious university.

The school in Cambridge, Massachusetts quickly slammed the move as “unlawful” and said it would hurt both the campus and the country, while one student said the community was “panicking.”

Trump is furious at Harvard, which has produced 162 Nobel prize winners, for rejecting his demand that it submit to oversight on admissions and hiring over his claims that it is a hotbed of anti-Semitism and “woke” liberal ideology.

The loss of such a large proportion of the student body could prove to be a huge financial blow to Harvard, which charges tens of thousands of dollars a year in tuition.

“Effective immediately, Harvard University’s Student and Exchange Visitor (SEVIS) Program certification is revoked,” Homeland Security Secretary Kristi Noem wrote in a letter to the Ivy League institution, referring to the main system by which foreign students are permitted to study in the United States.

Harvard, which has sued the government over a separate raft of punitive measures, quickly fired back, calling the move “unlawful.”

“We are fully committed to maintaining Harvard’s ability to host our international students and scholars,” it said in a statement, adding that it was working to offer students guidance and support.

“This retaliatory action threatens serious harm to the Harvard community and our country, and undermines Harvard’s academic and research mission.”

Karl Molden, an international student from Austria, said he had applied to study at Oxford in Britain because he feared such measures.

“It’s scary and it’s saddening,” the 21-year-old government and classics student told AFP.

“I love Harvard, and getting into the school has been the greatest privilege of my life.

“It’s definitely going to change the perception of… students who (might) consider studying there — the US is getting less of an attractive spot for higher education.”

Leaders of the Harvard chapter of the American Association of University Professors called the move “the latest in a string of nakedly authoritarian and retaliatory moves against America’s oldest institution of higher education.”

“The Trump administration is unlawfully seeking to destroy higher education in the United States. It now demands that we sacrifice our international students in the process. Universities cannot acquiesce to such extortion,” it said.

‘Everyone’s Panicking’

Last month, Trump threatened to stop Harvard from enrolling foreign students if it did not agree to government demands that would put the private institution under outside political supervision.

“As I explained to you in my April letter, it is a privilege to enroll foreign students,” Noem wrote.

“All universities must comply with Department of Homeland Security requirements, including reporting requirements under the Student and Exchange Visitor Program regulations, to maintain this privilege,” she said.

“As a result of your refusal to comply with multiple requests to provide the Department of Homeland Security pertinent information while perpetuating an unsafe campus environment that is hostile to Jewish students, promotes pro-Hamas sympathies, and employs racist ‘diversity, equity, and inclusion’ policies, you have lost this privilege.”

More than 27 percent of Harvard’s enrollment was made up of foreign students in the 2024-25 academic year, according to university data.

Fourth-year US student Alice Goyer told AFP “no one knows” what the development would mean for international students already enrolled.

“We just got the news, so I’ve been getting texts from a lot of international friends, and I think everyone’s just — no one knows,” she said.

“Everyone’s panicking a bit.”

On whether students would willingly transfer to other institutions, as suggested by Noem in the letter, Goyer said, “I doubt people would do that.”

“I would hope maybe there’s going to be a legal battle that’ll take place.”


© Agence France-Presse

Nona Biosciences Collaboration Partner Pfizer Announces Presentation of Phase 1 Clinical Study Design on MesoC2, an MSLN-Targeting ADC, at the 2025 ASCO Annual Meeting

CAMBRIDGE, Mass., May 23, 2025 /PRNewswire/ — Nona Biosciences, a global biotechnology company providing integrated solutions from “Idea to IND” (I to ITM), today announced that its collaborator, Pfizer, will present an abstract detailing the first-in-human Phase 1 clinical study design of MesoC2 (HBM9033/PF-08052666), a first-in-class mesothelin (MSLN)-targeting antibody-drug conjugate (ADC), at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.

MesoC2, originally developed using Nona’s proprietary Harbour Mice® and integrated ADC platforms, was licensed to Pfizer in December 2023 under a global rights agreement. Pfizer is currently evaluating the ADC in a Phase 1, open-label study in patients with advanced solid tumors, including mesothelioma, platinum-resistant ovarian cancer (PROC), pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), endometrial cancer (EC), and colorectal cancer (CRC).

Poster Presentation at the 2025 ASCO Annual Meeting
Title: A phase 1 study to evaluate the safety and tolerability of the antibody–drug conjugate (ADC) MesoC2 (PF-08052666) in patients with advanced solid tumors
Abstract Number: TPS3163
Poster Board Number: 475a
Session Title: Poster Session – Developmental Therapeutics – Molecularly Targeted Agents and Tumor Biology
Session Date and Time02 June 2025; 1:30 PM-4:30 PM (CDT)

Key Highlights from the Presentation:

  • MesoC2 is an ADC composed of a human IgG1 anti-MSLN monoclonal antibody conjugated to a cleavable tripeptide linker carrying a topoisomerase 1 inhibitor (TOP1i) payload (average drug-to-antibody ratio of 8).
  • MesoC2 has shown potent antitumor efficacy in in vitro assays and xenograft models and an acceptable safety profile in cynomolgus monkeys.
  • The Phase 1 trial (NCT06466187) will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy per RECIST v1.1 criteria of MesoC2 in up to 365 patients across dose escalation, optimization, and expansion cohorts.

“We are excited to see Pfizer advancing MesoC2 into clinical development rapidly, highlighting the potential of Nona’s Harbour Mice® and integrated ADC platforms to deliver innovative cancer therapies,” said Dr. Jingsong Wang, Chairman of Nona Biosciences. “The initiation of this Phase 1 trial marks a significant milestone in our collaboration and underscores our shared commitment to addressing unmet needs in oncology.”

Pfizer’s presentation at the 2025 ASCO Annual Meeting will provide further insights into the trial design. Additional details on the study can be found at ClinicalTrials.gov (NCT06466187).

About MesoC2 (HBM9033/PF-08052666)

MesoC2 (HBM9033/PF-08052666) is an ADC drug that targets human MSLN, a tumor-associated antigen (TAA) upregulated in various solid tumors. The fully human monoclonal antibody (mAb) in MesoC2 is derived from the Harbour Mice® platform and possesses well-tuned properties, exhibiting reduced binding to soluble MSLN while maintaining strong binding and internalization to membrane-bound MSLN. The unique design of the mAb was created to enhance potency in various preclinical tumor models with differing MSLN expression levels, positioning MesoC2 as a potential globally best-in-class therapeutic option.

About Nona Biosciences

Nona Biosciences is a global biotechnology company committed to cutting edge technology innovation and providing integrated solutions from “Idea to IND” (I to ITM), ranging from target validation and antibody discovery through preclinical research. The integrated antibody and antibody-related discovery services with multiple modalities range from antigen preparation, animal immunization, single B cell screening, to antibody lead generation and engineering, developability assessment and pharmacological evaluation, leveraging advantages of Harbour Mice® platforms and the experienced therapeutic antibody discovery team.

Harbour Mice® generates fully human monoclonal antibodies in classical two light and two heavy chain (H2L2) format, and heavy chain only (HCAb) format. Integrating Harbour Mice® and a single B cell cloning platform, Nona Biosciences is focused on driving global inventions of transformative next-generation drugs. For more information, please visit: www.nonabio.com.

 

Tianlong Services Unveils AI-Powered Corporate Secretarial Compliance Solutions for Cost-Effective Compliance


SINGAPORE – Media OutReach Newswire – 23 May 2025 – Tianlong Services, a corporate and accounting service provider in Singapore, has launched a new AI-driven corporate secretarial compliance suite. It is designed to simplify compliance and make robust governance accessible to startups, small and medium-sized enterprises (SMEs), and growth-stage companies.

Tianlong Services Platform Page

By integrating automation and intelligent workflows, Tianlong Services is transforming traditionally manual corporate secretarial compliance tasks into fast, error-resistant processes. This includes digital automation of key functions such as ACRA filings, share capital changes, board resolutions, and annual returns.

“Our goal is simple. We are looking to make corporate secretarial compliance effortless, accurate, and affordable,” said Kay Teng, CEO at Tianlong Services. “We’ve reimagined secretarial work through automation, enabling businesses to focus on growth instead of paperwork.”

Key Features:

  • AI-Driven Document Management

Automates the preparation and submission of compliance documents, from director appointments to AGM minutes.

  • Smart KYC & Due Diligence

Uses Optical Character Recognition (OCR) and third-party integrations to perform real-time verification and risk screening of clients and directors.

  • Predictive Compliance Monitoring (Launching Q4 2025)

Flags potential filing delays, adjusts calendars for public holidays or company changes, and sends timely reminders.

  • Affordable Pricing

With packages starting at just $218/year, Tianlong Services offers tiered plans to meet varying business needs without compromising quality or regulatory adherence.

A Human-Centric Approach to Regulatory Automation

Tianlong Services’ hybrid model blends automation with expert human oversight. It also includes white-glove onboarding, flexible support (via email, WhatsApp, or phone), and personalised check-ins to ensure clients are comfortable with the technology.

“This is more than just a tech upgrade. By combining automation with expert oversight, we’re offering businesses a more reliable way to meet regulatory obligations without the cost and complexity of traditional methods,” revealed Kay Teng, CEO at Tianlong Services.

The launch of this corporate secretarial compliance solution positions Tianlong Services as a regtech disruptor, offering a clear alternative to outdated manual systems that are often costly and error-prone. With regulatory automation gaining traction in Singapore’s corporate industry, the firm’s AI-powered solutions arrive at a critical time for founders, compliance officers, and lean business teams seeking smarter ways to stay compliant.

Hashtag: #TianlongServices

The issuer is solely responsible for the content of this announcement.

About Tianlong Services

Tianlong Services is an accounting and provider in Singapore. With a focus on lean and efficient operations, the company aims to help businesses reduce operational inefficiencies while improving decision-making through simplified financial reporting and actionable insights.

Microsoft Hong Kong and HKSTP join forces to introduce “TechConnect” co-incubation programme to empower global startups growing in Hong Kong

A collaboration to empower startups’ ambition, turning vision into momentums


HONG KONG SAR – Media OutReach Newswire – 23 May 2025 – Microsoft Hong Kong and the Hong Kong Science and Technology Parks Corporation (HKSTP) announced the launch of “TechConnect”, a 12-month co-incubation programme designed to empower local and global startups seeking to establish and scale their presence in the Hong Kong market. As part of Microsoft Hong Kong’s annual project “HKonnect+”, this collaborative initiative will mainly focus on driving innovation in smart city solutions, particularly within the burgeoning sectors of property technology, marketing technology, and retail solutions. By leveraging the strength and resources of Microsoft Hong Kong and HKSTP, the collaboration aims to provide comprehensive, end-to-end support to promising startups, facilitating their successful entry and growth within Hong Kong’s thriving tech ecosystem.

The collaboration was introduced in an opening ceremony by representatives from Microsoft Hong Kong and HKSTP, which underscores a shared commitment to fostering innovation and supporting the development of cutting-edge technologies in Hong Kong.

Application to the “TechConnect” programme is now opened. Local and overseas startups are encouraged to apply via https://bit.ly/43m2eAz .

Unparalleled benefits for participating startups to pave way for success

The “TechConnect” programme offers a suite of unparalleled benefits designed to accelerate the growth and success of participating startups, which will be supported by the unique resources of Microsoft Hong Kong and HKSTP.

Benefits that are going to be provided by Microsoft Hong Kong shed light on financial and technical support and business matching opportunities, including over HKD$1,100,000 in Microsoft Azure credits, granting startups free access to a wide range of Microsoft tools and exclusive offers, including GitHub Enterprise, Azure OpenAI Service, and VS Code, enabling them to leverage powerful technology for building and scaling their solutions. Participants will also benefit from comprehensive training workshops conducted by industry experts, covering key areas such as business strategy, technology development, and market entry. Ultimately, the programme will culminate in an exclusive DEMO Day, where startups will have the opportunity to pitch their solutions to leading investors, industry partners, and potential clients, fostering valuable business matching opportunities.

Meanwhile, HKSTP will offer up to HKD$100,000 through its Ideation Programme, providing crucial financial assistance during the early development stage of the tech companies. Startups will also gain access to co-working space, fostering a collaborative and productive environment. Eligible startups will also have the opportunity to apply for additional funding via HKSTP’s Incubation Programme, further fuelling their growth and expansion.

In addition, both parties will also jointly provide expert training, coaching, and unlimited learning resources on technology enablement and business growth. Exclusive startups offers, such as perks from LinkedIn, Stripe Atlas, Bubble, and other trusted partners, will also be included.

Henry Li, Head of Global Partner Solutions at Microsoft Hong Kong shared, “We are pleased to launch this groundbreaking co-incubation programme with HKSTP, which further strengthens Microsoft Hong Kong’s “HKonnect+” vision. By combining our cutting-edge technology resources and global industry expertise with HKSTP’s invaluable local market insights and established network, we are creating a powerful, synergistic ecosystem for innovation and accelerated growth, which will significantly reduce the hurdles startups face when they wish to establish presence in the Hong Kong market. We are eager to witness the tangible and positive impact these startups will have on Hong Kong’s future, driving technological advancement and improving the lives of our citizens.”

Derek Chim, Head of Startup Ecosystem and Development at HKSTP added, “We are thrilled to partner with Microsoft Hong Kong to launch the co-incubation programme. By providing essential support from funding, infrastructure to strategic support tailored to the unique challenges startups commonly encounter, we are empowering local and global innovators to scale up by bringing their transformative solutions to our city. We are looking forward to receiving exciting proposals that will create positive impact to Hong Kong’s innovation and technology landscape.”

Hashtag: #MicrosoftHongKong

The issuer is solely responsible for the content of this announcement.

About Microsoft

Microsoft (Nasdaq “MSFT” @microsoft) creates platforms and tools powered by AI to deliver innovative solutions that meet the evolving needs of our customers. The technology company is committed to making AI available broadly and doing so responsibly, with a mission to empower every person and every organization on the planet to achieve more.

About Hong Kong Science and Technology Parks Corporation

Hong Kong Science and Technology Parks Corporation (HKSTP) is Hong Kong’s largest innovation and technology incubator, serving a vibrant community of over 24,000 professionals. With more than 2,200 tech startups from over 26 countries / regions, HKSTP offers end-to-end incubation support—from ideation to scale-up—alongside world-class R&D facilities and infrastructure. As a leading driver of innovation, HKSTP propels to thrive and grow in Hong Kong and beyond.

The CamperKit, a Swiss Army Knife of tech gadgets for outdoor activities launches today on Kickstarter

This modular tool features 10+ accessories designed to meet diverse needs such as a jet fan, handheld fan, camping light, arc lighter, power bank, and air pump

HONG KONG, May 23, 2025 /PRNewswire/ — Aecooly, a tech brand focused on outdoor activities, has just launched the Kickstarter campaign for the CamperKit, an all-in-one modular tool that features 10+ interchangeable modules. Thanks to a magnetic quick-connect system, campers can attach the different modules (from fans to lights, arc lighters, and water pumps) to the Smart Controller, equipped with a 25.9Wh battery. The CamperKit Kickstarter campaign will run until July 21st ET and pledges start from $89.

Campers can already order their CamperKit  in this link !

ABOUT THE AECOOLY CAMPERKIT

This modular outdoor tool comes equipped with 10+ interchangeable modules that meet diverse needs during outdoor activities. While the Smart Controller provides power and control, the 10+ additional modules are designed to provide power, light, and even fresh air. The CamperKit comes equipped with a 25.9Wh battery and each module has been designed with a magnetic quick-connect interface that allows for quick and easy interchange.

Moreover,most travelers or campers tend to bring a lot of gear just in case, such as fans, alarms, camping lights, and more—even if not all of them are used. However, carrying all these items can be quite bulky. CamperKit’s lightweight and modular design allows users to be fully equipped without the heavy burden, making it the perfect companion for outdoor adventures.

Below you can find a list of the different modules that will come bundled with the CamperKit:

  1. Smart Controller
  2. Jet Fan Mod
  3. High-Speed Fan Mod
  4. Camping Fan Mod
  5. Ambient Light Mod
  6. Flashlight Mod
  7. Camping Lantern Mod
  8. Arc Lighter Mod
  9. Air Pump Mod
  10. Water Pump Mod
  11. Alarm Mod
  12. Charger Mod

Early supporters can grab their CamperKit unit for just $89, with only 500 units available. Aecooly encourages customers to secure their units during the Kickstarter campaign to enjoy the best price and avoid missing out.

In addition, Aecooly also offers a range of cooling fans designed specifically for summer comfort.

ASSETS

You can find pictures and other useful information about the Aecooly CamperKit at this link.

CONTACT

You can contact us at marketing@aecooly.com.

SOCIAL MEDIA

ABOUT AECOOLY

Aecooly is a passionate team dedicated to developing innovative outdoor appliances. We specialize in combining aesthetics with functionality, leveraging advanced technology and creative design to craft stylish handheld fans and versatile outdoor gear. Our mission is to provide users with a refreshing and natural cooling experience while delivering products that are both visually appealing and highly practical. At Aecooly, we aim to brighten your everyday life with innovation, bringing comfort and joy to every moment. Wherever life takes you, Aecooly is by your side, making every adventure cool and effortless.

Everest Medicines Announces NEFECON® Inclusion in China’s Clinical Practice Guideline for IgA Nephropathy and IgA Vasculitis in Chinese Adults (For Public Review)

SHANGHAI, May 23, 2025 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, announced that NEFECON® has been included in the “Clinical Practice Guideline for IgA Nephropathy and IgA Vasculitis in Chinese Adults (For Public Review)” (hereinafter referred to as the “Guideline (Draft)”) on May 21, recommending the etiological treatment with a 9-month course of NEFECON® for all primary immunoglobulin A nephropathy (IgAN) patients who are at risk for disease progression, irrespective of proteinuria levels (2B).

The Guideline (Draft) was presented by Professor Hong Zhang and Professor Jicheng Lv from Peking University First Hospital, during the IgA Nephropathy Forum and IIgANN-China Annual Meeting. It aims to provide crucial guidance for the standardization and optimization of IgA nephropathy diagnosis and treatment. The Guideline (Draft) emphasizes a new disease management strategy of Treat the cause, Treat early, Treat comprehensively.

The Guideline (Draft) recommends that patients with proteinuria ≥ 0.5g/day (or equivalent levels) undergo a renal biopsy and initiate treatment. The treatment goal is to slow the estimated glomerular filtration rate (eGFR) loss to less than 1 ml/min per year. In addition to the two core indicators of proteinuria and eGFR, the Guideline (Draft) also emphasizes routine monitoring of hematuria.

For the first time, the guideline introduces interventions targeting immune-mediated injury, particularly the formation of pathogenic IgA (Gd-IgA1), a key driver of pathogenesis to IgAN. For patients at risk of disease progression, the guideline proposes addressing both symptoms of renal function decline, and initiating therapies targeting immune-mediated injury and CKD progression. NEFECON® is recommended as the preferred treatment to reduce Gd-IgA1. Once short-term treatment goals, namely proteinuria remission (defined as proteinuria < 0.5 g/day, ideally < 0.3 g/day) and stable renal function, are achieved, low-dose maintenance or repeated safe and effective immunotherapy can be considered together with supportive care to ensure that eGFR declines by less than 1 ml/min per year.

“Compared to European and American populations, China has a large IgAN patient population. Chinese IgAN patients experience more rapid disease progression and poorer prognosis. A majority of IgAN patients face the risk of progressing to end-stage renal disease during their lifetime, placing a heavy burden on patients and society.” Said Professor Zhang Hong with Peking University First Hospital, a member of the global steering committee for the Phase 3 clinical trial NefIgArd, chairman of the Chinese Collaborative Group of the International IgAN Federation. “Therefore, IgAN patients require early diagnosis, and a comprehensive treatment approach that spans early intervention, initial therapy, and maintenance therapy. The Guideline (Draft) offers important guidance for clinical practice of IgA nephropathy treatment in China.”

“IgA nephropathy is the most common form of chronic glomerulonephritis worldwide, affecting 40% to 50%[1,2] of kidney biopsy patients in Asian populations, particularly in China. Fifteen years after diagnosis, the kidney survival rate can drop to as low as 40%[1]. This makes the development of guidelines tailored to the Chinese population particularly important.” said Professor Jicheng Lv from Peking University First Hospital. “The Guideline (Draft) updates the treatment strategies and medications for IgAN in China, further standardizing its diagnosis and treatment. It establishes a novel care strategy for Chinese IgAN patients, emphasizing the principles of Treat the cause, Treat early, Treat comprehensively. It recommends treatment with a 9-month course of NEFECON® for IgAN patients at risk of disease progression (2B).”

“We are delighted to see NEFECON® included in the Guideline (Draft), marking a milestone that not only provides Chinese physicians a scientific and precise treatment option but also promises greater benefits and improved quality of life for Chinese IgAN patients.” said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “As the first and only etiological treatment for IgAN fully approved in China, the United States, and Europe, NEFECON® significantly slows eGFR decline, reduces proteinuria, and preserves kidney function. NEFECON® has established itself as a first-line cornerstone therapy for IgAN. Its inclusion in the draft guideline further validates its outstanding clinical advantages, redefining treatment standards and entering a new era of standardized care.”

NEFECON®, as the only in-disease IgA nephropathy (IgAN) treatment has been included in the “KDIGO 2024 Clinical Practice Guideline For The Management Of Immunoglobulin A Nephropathy (IgAN) And Immunoglobulin A Vasculitis (IgAV) (public review draft), recommending treatment with a 9-month course of NEFECON® for patients who are at risk of progressive kidney function loss with IgAN (2B).

Results from the Phase 3 clinical study NefIgArd of the Chinese population shows that NEFECON® reduces kidney function decline by 66%, and delays disease progression to dialysis or kidney transplantation by 12.8 years. During the 2-year treatment and observation period, NEFECON® also demonstrated clinically significant kidney function protection. With the Phase 3 clinical study and real-world evidence, NEFECON® not only fills the gap in etiological treatment for IgAN both domestically and internationally, but also provides clinicians with more compelling treatment options, giving patients a valuable treatment window.

Since May 2025, NEFECON® is indicated to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression, irrespective of proteinuria levels. This approval marks NEFECON® as the first and only etiological treatment for IgA nephropathy (IgAN) to receive full approval in China. NEFECON® was also included in the National Reimbursement Drug List in November 2024.

About NEFECON®

NEFECON® is a patented oral, delayed release formulation of budesonide, a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity that undergoes substantial first pass metabolism. The formulation is designed as a delayed release capsule that is enteric coated so that it remains intact until it releases budesonide to the distal ileum. Each capsule contains coated beads of budesonide that target mucosal B-cells present in the ileum where the disease originates, as per the predominant pathogenesis models.

In June 2019, Everest Medicines entered into an exclusive, royalty-bearing license agreement with Calliditas Therapeutics, which gives Everest Medicines exclusive rights to develop and commercialize NEFECON® in mainland China, Hong Kong, Macau, Taiwan (China) and Singapore. The agreement was extended in March 2022 to include South Korea as part of Everest Medicines’ territories.

About Everest Medicines

Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the company’s core therapeutic areas of renal diseases, infectious diseases and autoimmune disorders. For more information, please visit its website at www.everestmedicines.com.

Forward-Looking Statements:

This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.

References:

1.       Shen X, et al. Nephrol Dial Transplant. 2024 Nov 19: gfae252.

2.       Li G, et al. J Nephrol . 2025 Mar 26. doi: 10.1007/s40620-025-02261-1. Online ahead of print.

SUNMI Opens Its First North American Store in Atlanta

ATLANTA, May 23, 2025 /PRNewswire/ — On May 22, 2025, SUNMI, a global leader in smart business IoT solutions, celebrated the grand opening of its first North American store in Atlanta’s central business district, unveiling the upgraded digital transformation experience space “SUNMI Home 2.0.” The event was attended by SUNMI founder Jack Lin, rotating president and CMO Sam Su, and key ecosystem partners, marking a significant milestone. This flagship store embodies SUNMI’s innovative “Regional Headquarters & Flagship Experience Center” model, aimed at accelerating localized digital transformation in the region.

New Third-Generation Product Matrix: Setting a Benchmark for Smart Terminals

SUNMI Home 2.0 showcases its third-generation flagship products, including the global debut of the SUNMI CPad, L3, M3, and the new category Flex 3. This extensive array of smart terminals is supported by SUNMI’s integrated software capabilities, and offers the SUPER Solution dual-system and Hyper Wi-Fi network solutions. Alongside global partners, SUNMI is building a digital engine for the restaurant, retail, and logistics sectors across North America.

SUNMI Home 2.0: A Powerhouse for Business Innovation

Unlike traditional retail outlets, this upgraded SUNMI Home 2.0 seamlessly combines offline experiences with online services:

  1. Offline Operations: The store will host “Channel Co-Building Days” and “Industry Open Days,” inviting partners to engage in customized solution discussions and collaborating with local businesses for regular digital transformation practice sessions. Local retail and restaurant representatives demonstrated how SUNMI devices enhance space utilization and customer experience at the grand opening.
  2. Online Upgrades: The upcoming “SUNMI Home” version will integrate 3D VR experiences and an intelligent recommendation system, allowing users to easily locate nearby service points through a map feature, offering tailored industry solutions with a single tap.

Strategic Expansion: Localized Strategies Activate the North American Market

Sam Su highlighted that “Atlanta is a central hub connecting the east and west coasts of North America. Leveraging this headquarters, regional offices and local warehouses along with employees, we will provide customized BIoT solutions through our global supply chain and production network. Our ecosystem partners are essential as we work together to deliver comprehensive industry solutions that enhance user experience.”

Looking Ahead: Driving Business 4.0 Growth

With the Atlanta flagship store operational, SUNMI plans to open five additional SUNMI Homes in the U.S. by 2025, improving customer experience and collaboration through interconnected services.